Search

Displaying results 1521 - 1530 of 10000 in total
  1. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring
  2. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

    Categories: Heterocyclic Compounds, 1-Ring, Adrenergic alpha-2 Receptor AgonistsSynonyms: (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid
  3. Drug

    Losartan

    go.drugbank.com/drugs/DB00678
    ApprovedInvestigational

    [L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. … Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.

    Synonyms: 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole, (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanolMixtures: LOSARTAN E IDROCLOROTIAZIDE EG, LOSARTAN E IDROCLOROTIAZIDE EG
  4. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    with first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818]. … Based on its tolerability and safety profile, remestemcel-L is a promising alternative to second-line immunosuppressive agents [A31818].

    Synonyms: Remestemcel-L
  5. Target

    Orf protein

    go.drugbank.com/bio_entities/BE0003165
    TargetEscherichia coli

    The B subunit is responsible for the binding of the holotoxin to specific receptors on the target cell surface, such as globotriaosylceramide (Gb3) in human intestinal microvilli.

    Synonyms: Shiga toxin 2 variant e B-subunit
  6. Target

    5-hydroxytryptamine 3 receptor

    go.drugbank.com/bio_entities/BE0009860
    TargetHumans

    Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons … Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons

    Synonyms: 5-HT3-E
  7. Target

    5-hydroxytryptamine receptor 3

    go.drugbank.com/bio_entities/BE0010272
    TargetHumans

    Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons … Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons

    Synonyms: 5-HT3-E
  8. Drug

    Buprenorphine

    go.drugbank.com/drugs/DB00921
    ApprovedIllicitInvestigationalVet approved

    [L46571] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid … Clinically, this results in a slow onset of action and a clinical phenomenon known as the "ceiling effect" where once a certain dose is reached, buprenorphine's effects plateau.

    Mixtures: BUPRENORFINA E NALOXONE ETHYPHARM, BUPRENORFINA E NALOXONE ETHYPHARMCategories: Drugs Used in Opioid Dependence, Drugs Used in Addictive Disorders
  9. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … [A192789] Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote

    Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: IMFINZI® 50 MG/ML CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN, IMFINZI 120 MG/2.4 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET
  10. Drug

    Ezetimibe

    go.drugbank.com/drugs/DB00973
    ApprovedInvestigational

    [A33313] In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings … C1-Like 1 (NPC1L1), and is unique in that it does not affect the absorption of fat-soluble nutrients such as fat-soluble vitamins, triglycerides, or bile acids.

    Mixtures: EZETIMIBE E SIMVASTATINA EG, EZETIMIBE E SIMVASTATINA EGCategories: P-glycoprotein substrates, Cytochrome P-450 CYP2C8 Inhibitors